NCT03417921View on ClinicalTrials.gov

A Study of ABTL0812 in Pancreatic Cancer

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

April 26, 2023

Study Completion Date

December 31, 2025

Conditions
Pancreatic Cancer
Interventions
DRUG

ABTL0812

ABTL0812 in combination with gemcitabine and nab-paclitaxel

DRUG

Gemcitabine and nab-paclitaxel

Gemcitabine and nab-paclitaxel as standard pattern

Trial Locations (1)

08190

Marc Cortal, Barcelona

Sponsors
All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

lead

Ability Pharmaceuticals SL

INDUSTRY

NCT03417921 - A Study of ABTL0812 in Pancreatic Cancer | Biotech Hunter | Biotech Hunter